Q2035366 (Q2035366): Difference between revisions
Jump to navigation
Jump to search
(Created a new Item) |
(Changed an Item) |
||
| Property / Italian Kohesio ID | |||
| Property / Italian Kohesio ID: 5la16018bp000000044 / rank | |||
Normal rank | |||
Revision as of 01:52, 12 March 2020
Project in Italy financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project in Italy financed by DG Regio |
Statements
188,379.49 Euro
0 references
376,758.97 Euro
0 references
50.000001327108414 percent
0 references
12 December 2016
0 references
6 July 2019
0 references
EXIRIS S.R.L.
0 references
41°53'35.95"N, 12°28'58.55"E
0 references
GLI ANTICORPI SONO AGENTI TERAPEUTICI DI GRANDE SUCCESSO CHE VENGONO UTILIZZATI PER IL TRATTAMENTO DI MALATTIE ONCOLOGICHE, INFIAMMATORIE, AUTO IMMUNI E CARDIOVASCOLARI. IL NUMERO DI FARMACI BASATI SU ANTICORPI Ê IN CONTINUA CRESCITA (Italian)
0 references
Identifiers
F81B18000200007
0 references